HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>Whether WeiMai’s business model can operate sustainably and effectively depends on whether it can establish long-term/stable relationship with hospitals/doctors, as they are the key stakeholders to attract/retain the downstream customers.</li>
<li>However, the relationship between WeiMai and the hospital network may not be solid, thereby shaking the foundation of the entire business model. Gross margin level is unsatisfactory compared with peers.</li>
<li>Post-Money valuation after Series D+ Financing was US$559 million. Due to the concerns on business model and the profitability, WeiMai’s valuation should be lower than <a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology</a>.</li>
</ul>


Whether WeiMai’s business model can operate sustainably and effectively depends on whether it can establish long-term/stable relationship with hospitals/doctors, as they are the key stakeholders to attract/retain the downstream customers.
However, the relationship between WeiMai and the hospital network may not be solid, thereby shaking the foundation of the entire business model. Gross margin level is unsatisfactory compared with peers.
Post-Money valuation after Series D+ Financing was US$559 million. Due to the concerns on business model and the profitability, WeiMai’s valuation should be lower than Ping An Healthcare and Technology.


Pre-IPO WeiMai - The Pain Points Behind the Business Model

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of October 31st.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent, Meituan, Li Auto.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of October 31st.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent, Meituan, Li Auto.


HK Connect Flows Weekly (Oct 31st): CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent

<ul>
<li>We analysed the earning revision of component stocks of HS TECH in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd, BYD, Bidu, Sensetime, Tme, Asmpt.</li>
</ul>


We analysed the earning revision of component stocks of HS TECH in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd, BYD, Bidu, Sensetime, Tme, Asmpt.


HS TECH Index Earning Revision (Oct): MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd

<ul>
<li>We analysed the earning revision of component stocks of HSCEI in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM, PING AN INSURANCE, China Life, Ping An, Pop Mart, Meituan, Jd, Jd Health.</li>
</ul>


We analysed the earning revision of component stocks of HSCEI in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM, PING AN INSURANCE, China Life, Ping An, Pop Mart, Meituan, Jd, Jd Health.


HSCEI Index Earning Revision (Oct): Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM

Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Macroeconomics

<ul>
<li>China has announced that it will significantly boost the share of domestic consumption in its next five years, while maintaining tech and manufacturing as top priorities.</li>
<li>The nation's banks will be instrumental in providing consumption financing to spur a virtual growth driver for the economy.  Easing monetary policies will be in addition to the trade-in programs.</li>
<li>Consumer in service sectors like e-commerce, travel &amp; tourism, healthcare, elderly care and AI will benefit from increasing consumption.  Local brands stand to gain market share against foreign competitors.</li>
</ul>


China has announced that it will significantly boost the share of domestic consumption in its next five years, while maintaining tech and manufacturing as top priorities.
The nation's banks will be instrumental in providing consumption financing to spur a virtual growth driver for the economy.  Easing monetary policies will be in addition to the trade-in programs.
Consumer in service sectors like e-commerce, travel &amp; tourism, healthcare, elderly care and AI will benefit from increasing consumption.  Local brands stand to gain market share against foreign competitors.


CHINA HOUSEHOLD CONSUMPTION: Unlocking Growth Potential in Five-Year Plan

China

JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health International (6618 HK)

Pre-IPO WeiMai - The Pain Points Behind the Business Model

WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Oct 31st): CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent,...

Ke Yan, CFA, FRM

HS TECH Index Earning Revision (Oct): MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd

We analyzed HS TECH's consensus for Oct 2025 and highlighted changes of EPS in MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd, BYD,...

Ke Yan, CFA, FRM

HSCEI Index Earning Revision (Oct): Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM

We analyzed HSCEI's consensus for Oct 2025 and highlighted changes of EPS in Pop Mart Intl (9992 HK), MEITUAN (3690 HK), JD Health (6618 HK), China...

Ke Yan, CFA, FRM

CHINA HOUSEHOLD CONSUMPTION: Unlocking Growth Potential in Five-Year Plan

China has announced that it will significantly boost the share of domestic consumption in its next five years, while maintaining tech and...

David Mudd

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO WeiMai - The Pain Points Behind the Business Model

​WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Oct 31st): CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, SMIC, Alibaba, China Mobile, CSPC Pharma, Tencent,...

Ke Yan, CFA, FRM

HS TECH Index Earning Revision (Oct): MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd

We analyzed HS TECH's consensus for Oct 2025 and highlighted changes of EPS in MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd, BYD,...

Ke Yan, CFA, FRM

HSCEI Index Earning Revision (Oct): Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM

We analyzed HSCEI's consensus for Oct 2025 and highlighted changes of EPS in Pop Mart Intl (9992 HK), MEITUAN (3690 HK), JD Health (6618 HK), China...

Ke Yan, CFA, FRM

CHINA HOUSEHOLD CONSUMPTION: Unlocking Growth Potential in Five-Year Plan

China has announced that it will significantly boost the share of domestic consumption in its next five years, while maintaining tech and...

David Mudd

WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...